0KCC.LSE Insight Molecular Diagnostics
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 0KCC.LSE undervalued?
Graham numberThe Graham number of Insight Molecular Diagnostics cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Insight Molecular Diagnostics fundamental analysis
No fundamental analysis for Insight Molecular Diagnostics yet.
Insight Molecular Diagnostics stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Insight Molecular Diagnostics
Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immun…
Full company profileInsight Molecular Diagnostics financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Insight Molecular Diagnostics annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | - | - | - | 1.22M | 2.20M | 958K | 1.50M | 1.88M | 4.05M | 542K |
| Gross Profit | -387K | -580K | -559K | -344K | -639K | -2.79M | -5.24M | 501K | -666K | 190K | -2.18M |
| Operating Income | -11.1M | -18.8M | -14.6M | -22.2M | -31.7M | -23.8M | -28.8M | -25.1M | -23.2M | -30.6M | -38.8M |
| EBITDA | -10.8M | -18.3M | -14.0M | -21.9M | -30.5M | -48.5M | -13.3M | -23.1M | -59.0M | -28.4M | -36.2M |
| Net Income | -11.2M | -19.4M | -15.8M | -22.4M | -29.9M | -64.1M | -72.9M | -27.8M | -60.7M | -50.2M | -31.1M |
| EPS | -8.42 | -13 | -8.32 | -8.74 | -9.14 | -14 | -13 | -3.63 | -4.64 | -1.65 | -0.85 |
| Balance Sheet | |||||||||||
| Total Assets | 14.4M | 10.2M | 9.52M | 39.9M | 55.4M | 160M | 100M | 74.9M | 35.1M | 25.8M | 29.4M |
| Total Liabilities | 4.59M | 5.81M | 6.10M | 9.02M | 21.9M | 94.3M | 60.5M | 49.3M | 47.4M | 57.2M | 50.7M |
| Shareholders' Equity | 9.86M | 4.40M | 3.42M | 30.8M | 33.5M | 65.2M | 39.6M | 25.6M | -12.3M | -31.5M | -21.3M |
| Cash & Short-term Investments | 12.4M | 8.36M | 8.46M | 22.5M | 7.82M | 33.9M | 20.4M | 9.43M | 8.64M | 12.3M | 18.5M |
| Total Debt | 512K | 2.50M | 1.72M | 5.94M | 8.63M | 5.68M | 3.54M | 2.87M | 3.66M | 3.50M | 2.63M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -7.52M | -13.4M | -11.6M | -19.7M | -26.0M | -35.9M | -45.6M | -23.3M | -20.7M | -22.2M | -33.8M |
| Capital Expenditure | 106K | 91.0K | 31.0K | 918K | 1.23M | 2.25M | 4.34M | 281K | 516K | 3.19M | 2.78M |
| Free Cash Flow | -7.63M | -13.5M | -11.7M | -20.6M | -27.2M | -38.2M | -49.9M | -23.6M | -21.2M | -25.4M | -36.6M |
| Ratios | |||||||||||
| ROE | -113.2% | -440.0% | -460.2% | -72.7% | -89.4% | -98.3% | -184.1% | -108.5% | - | - | - |
| ROA | -77.3% | -189.7% | -165.5% | -56.3% | -54.0% | -40.2% | -72.8% | -37.1% | -172.9% | -195.0% | -105.6% |
| Net Profit Margin | - | - | - | - | -2,461.5% | -2,916.2% | -7,609.8% | -1,848.4% | -3,225.0% | -1,238.5% | -5,738.0% |
| Debt to Equity | 0.05x | 0.57x | 0.50x | 0.19x | 0.26x | 0.09x | 0.09x | 0.11x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Insight Molecular Diagnostics dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | USD 239K | 0.05 | - |
| 2020 | USD 14.0K | 0.00 | - |
| 2019 | - | - | - |
| 2018 | USD 96.0K | 0.05 | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 0.05:1 on Jul 25, 2023.
Who owns Insight Molecular Diagnostics
- Insiders 21.00%
- Institutions 57.54%
- Public & others 21.46%
- Free float 9.98M
Insight Molecular Diagnostics company profile
- Company name
- Insight Molecular Diagnostics
- Ticker
- 0KCC.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Commercial Services & Supplies
- Employees
- 55
- Fiscal year end
- December
- Address
- 2 International Plaza Dr., Nashville, TN, United States, 37217
- Phone
- 949 409 7600
- Website
- imdxinc.com
About Insight Molecular Diagnostics
Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The company also offers GraftAssureCore test, a blood test designed to measure dd-cfDNA using a novel PCR-based measurement platform, for potential patient registrants; GraftAssureIQ, a transplant monitoring assay to measure the donor-derived cell-free DNA; and GraftAssureDx, a decentralized transplant monitoring levels of donor-derived cell-free DNA in plasma following kidney transplantation to aid in the assessment of the probability of allograft rejection at the time of testing in conjunction with standard clinical assessments. In addition, it provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. for the development and commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. The company was formerly known as OncoCyte Corporation and changed its name to Insight Molecular Diagnostics Inc. in June 2025. Insight Molecular Diagnostics Inc. was incorporated in 2009 and is based in Nashville, Tennessee.
Insight Molecular Diagnostics management
10- Mr. Joshua RiggsPresident, CEO & Director · born 1983
- Ms. Andrea Susan JamesChief Financial Officer · born 1982
- Mr. James LiuVP of Accounting, Treasurer, Controller & Principal Accounting Officer · born 1996
- Mr. Yuh-Min Chiang Ph.D.Chief Technology Officer
- Dr. Ekkehard Schutz M.D., Ph.D.Chief Science Officer
- Mr. Peter HongVP, General Counsel & Secretary
- Mr. Steven TahmooressiVice President of Marketing
- Mr. Donnie PurtoSVP of Sales & Sales Operations
- Ms. Sandra O'DonaldSenior Vice President of Business Operations
- Dr. Paul R. Billings FACP, M.D., Ph.D.Consulting Chief Medical Officer · born 1952